DOCSLIB.ORG

Regeneron Pharmaceuticals Inc

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Regeneron Pharmaceuticals Inc. Watchdog Report ™ REGN (NASDAQ Global) | CIK:872589 | United States | SEC llings The new model for duciary analysis Sep 24, 2021 Jan 1, 2020 Jan 1, 2016 RECENT PERIOD HISTORICAL PERIOD Key Facts 10-Q led on Aug 5, 2021 for period ending Jun 2021 Business address: Tarrytown, New York, United States Reporting Irregularities RECENT HISTORICAL Industry: Pharmaceutical Preparation Manufacturing (NAICS 325412) Financial Restatements SEC ler status: Large Accelerated Filer as of Jun 2021 Index member: S&P 500, Russell 1000 Revisions Market Cap: $68.3b as of Sep 24, 2021 Out of Period Adjustments Annual revenue: $8.5b as of Dec 31, 2020 Late Filings Corporate Governance Impairments CEO: Leonard S. Schleifer MD since 1988 Changes in Accounting Estimates CFO: Robert E. Landry since 2013 Disclosure Controls 1st level Internal Controls Board Chairman: Roy P. Vagelos MD since 1995 Critical / Key Audit Matters Audit Committee Chair: NOT AVAILABLE 2nd level Anomalies in the Numbers RECENT HISTORICAL Auditor: PricewaterhouseCoopers LLP since 1989 Benford's Law Outside Counsel (most recent): Kirkland & Ellis LLP Paul Weiss Rifkind Wharton & Garrison LLP Beneish M-Score 3rd level Accounting Disclosure Complexity SEC Reviewer: (unknown) Securities & Exchange Commission Concerns 4th level RECENT HISTORICAL SEC Oversight SEC Letters to Management Revenue Recognition Non-GAAP Measures Litigation & External Pressures RECENT HISTORICAL Signicant Litigation Securities Class Actions Shareholder Activism Watchdog Research, Inc., offers both individual and group subscriptions, Cybersecurity data feeds and/or custom company reports to our subscribers. Management Review Subscribe: We have delivered 300,000 public company reports to over RECENT HISTORICAL 27,000 individuals, from over 9,000 investment rms and to 4,000+ public CEO Changes company corporate board members. CFO Changes How to analyze this company's Watchdog Insider Sales Report? Skip to the last page Pledged Securities Information in this report is effective Sep 24, 2021 and is taken from the Mergers & Acquisitions company's public nancial and regulatory lings. Latest ling 10-Q led Sales of Assets 08/05/2021. Over 75 accounting and data analysts scrutinize and review crucial information, footnotes, disclosures, etc., from these lings. Material Auditor Assessment facts are captured and processed using our proprietary methods which RECENT HISTORICAL identify key risk factors our readers need to know. Each Watchdog Report Auditor Changes represents 30 or more hours of analysis and processing. Auditor Experience Accounting and nancial disclosure data from Audit Analytics. Auditor Tenure Executive compensation data from Shore Group and Intrinio. Data from Sharadar. Audit Fees Data from Barchart via Quandl. Non-Audit Fees Data from Exchange Data International via Quandl. Watchdog Research, Inc. • www.watchdogresearch.com • [email protected] • (855) 820-6272 Overview Reporting Irregularities Anomalies in the Numbers SEC Concerns Litigation & External Pressures Management Review Auditor Assessment Peer Group Overview Price and Volume History This graph shows the price and trading history for Regeneron. Warning signs and red ags are marked on the graph according to their disclosure dates. 1 Aug 20, 2021 - Insider Sale 20 Jun 10, 2020 - Insider Sale 2 Aug 10, 2021 - Insider Sale 21 May 13, 2020 - Insider Sale 3 Aug 10, 2021 - Insider Sale 22 Apr 20, 2020 - Insider Sale 4 Jul 28, 2021 - Lawsuit: Ball v. Baker et al 23 Apr 16, 2020 - Insider Sale 5 Jul 22, 2021 - Lawsuit: Humana Inc v. Regeneron Pharmaceuticals Inc 24 Apr 13, 2020 - Insider Sale 6 Feb 8, 2021 - Critical / Key Audit Matters 25 Apr 8, 2020 - Insider Sale 7 Feb 2, 2021 - SEC letters to management 26 Apr 3, 2020 - Insider Sale 8 Feb 2, 2021 - Revenue Recognition 27 Mar 11, 2020 - Insider Sale 9 Dec 31, 2020 - Insider Sale 28 Feb 7, 2020 - Critical / Key Audit Matters 10 Dec 17, 2020 - Lawsuit: UnitedHealthcare Insurance Company et al v. Regeneron Pharm… 29 Dec 13, 2019 - Insider Sale 11 Dec 11, 2020 - Lawsuit: Regeneron Pharmaceuticals Inc v. United States Department of… 30 Dec 13, 2019 - Insider Sale 12 Oct 5, 2020 - Lawsuit: Allele Biotechnology & Pharmaceuticals Inc v. Regeneron Pharm… 31 Feb 7, 2019 - Change in Accounting Estimates 13 Jul 22, 2020 - Insider Sale 32 Dec 17, 2018 - Insider Sale 14 Jul 17, 2020 - Lawsuit: Regeneron Pharmaceuticals Inc v. Novartis Pharma AG et al 33 Dec 14, 2018 - Insider Sale 15 Jul 9, 2020 - Insider Sale 34 Sep 11, 2018 - Insider Sale 16 Jun 24, 2020 - Insider Sale 35 Mar 19, 2018 - Lawsuit: Novartis Vaccines and Diagnostics Inc et al v. Regeneron Phar… 17 Jun 24, 2020 - Lawsuit: United States of America v. Regeneron Pharmaceuticals Inc 36 Dec 20, 2017 - Insider Sale 18 Jun 19, 2020 - Lawsuit: Novartis Pharma AG et al v. Regeneron Pharmaceuticals Inc 37 Dec 13, 2017 - Insider Sale 19 Jun 12, 2020 - Insider Sale 38 Dec 13, 2017 - Insider Sale Watchdog Research, Inc. • www.watchdogresearch.com • [email protected] • (855) 820-6272 39 Sep 6, 2017 - Insider Sale 45 Mar 20, 2017 - Lawsuit: Sano Aventis US LLC et al v. Amgen Inc et al 40 Sep 1, 2017 - Insider Sale 46 Feb 9, 2017 - Impairment 41 Aug 24, 2017 - Insider Sale 47 Dec 19, 2016 - Insider Sale 42 Aug 9, 2017 - Insider Sale 48 Nov 16, 2016 - SEC letters to management 43 Aug 3, 2017 - Out of Period Adjustments 49 Nov 16, 2016 - Revenue Recognition 44 Apr 5, 2017 - Lawsuit: Immunex Corporation v. Sano et al 50 Feb 11, 2016 - Revisions Notications Important notications related to the company are listed here. Notications may come from the SEC, exchanges such as the NYSE or NASDAQ, or Watchdog Research. Examples of notications include announcements of bankruptcy proceedings, company name changes, and noncompliance with SEC regulations or exchange rules. There are no notications for Regeneron at least since 2016. Peer Group Peer groups are used by companies to benchmark executive compensation and performance. Each company identies its own peer group. Peer groups vary from company to company. Peer Group Companies Who Named Regeneron as a Peer Company Ticker Market Cap Company Ticker Market Cap Eli Lilly and Company LLY $222b Moderna, Inc. MRNA $174b AbbVie Inc. ABBV $191b Amgen Inc. AMGN $130b Merck & Co., Inc. MRK $186b CVS Health Corp. CVS $112b Bristol Myers Squibb Co. BMY $134b Regeneron Pharmaceuticals Inc. REGN $68.3b Amgen Inc. AMGN $130b Illumina Inc. ILMN $65.8b Gilead Sciences Inc. GILD $89.3b Agilent Technologies Inc. A $52.2b Regeneron Pharmaceuticals Inc. REGN $68.3b IQVIA Holdings, Inc. IQV $50.1b Vertex Pharmaceuticals Inc. VRTX $47.6b Vertex Pharmaceuticals Inc. VRTX $47.6b Biogen Inc. BIIB $43.5b Biogen Inc. BIIB $43.5b Seagen Inc. SGEN $29.4b Seagen Inc. SGEN $29.4b Watchdog Research, Inc. • www.watchdogresearch.com • [email protected] • (855) 820-6272 Peer Flag Comparison The return to a company’s stock is not the only measure of executive performance. Ethics matter, and growth can quickly reverse and gains evaporate if a company’s accounting and nancial reporting processes are not fundamentally sound and trustworthy. How does Regeneron's accounting quality compare to its peer group? REGN PEER GROUPFLAGS REGN PEER GROUPFLAGS Reporting Irregularities Litigation & External Pressures Financial Restatements 9 Signicant Litigation 9 Revisions 8 1 Securities Class Actions 1 8 Out of Period Adjustments 8 1 Shareholder Activism 8 1 Impairments 1 8 Cybersecurity 7 2 Changes in Accounting Estimates 3 6 Management Review Disclosure Controls 2 7 CEO Changes 4 3 2 Internal Controls 9 CFO Changes 1 3 5 Critical / Key Audit Matters 9 Insider Sales 6 3 Pledged Securities 9 Anomalies in the Numbers Benford's Law 7 2 Mergers & Acquisitions 6 3 Beneish M-Score 6 2 Sales of Assets 9 Accounting Disclosure Complexity 3 4 2 Auditor Assessment Auditor Changes 9 Securities & Exchange Commission Concerns SEC Oversight 9 Auditor Experience 9 SEC Letters to Management 9 Auditor Tenure 6 3 Revenue Recognition 6 3 Audit Fees 6 3 Non-GAAP Measures 9 Non-Audit Fees 4 5 Watchdog Research, Inc. • www.watchdogresearch.com • [email protected] • (855) 820-6272 About Watchdog Research, Inc. Watchdog Research, Inc. is an independent research provider and publisher of Watchdog Reports. Watchdog Reports identify red ags, issues, and other anomalies in nancial reporting. Our reports contain warning signs, red ags, material disclosures, and peer analysis for use in valuation, risk analysis, due diligence research, and idea generation. Watchdog Reports are designed to assist investment professionals fulll their duciary or suitability obligations and to help investors, executives, board members, regulators and educators learn what they need to know about publicly traded companies. The company is headquartered in Ave Maria, FL. Watchdog Research, Inc. utilizes over 75 specialists and analysts to provide accurate and timely Watchdog Research, Inc. information to our readers. 5072 Annunciation Cir. Suite 202 Ave Maria, FL 34142 Our management team is: [email protected] (855) 820-6272 CEO: Brian Lawe. Brian has been part of the corporate staff at The New York www.watchdogresearch.com Times Company and IBM. He has created and operated several technology companies including MyStoreCredit, OnPage Ideas and HelloCampus. He holds an MBA from Harvard Business School and a BBA from Texas Christian University. He and his wife have four children and live in the Naples, FL area. CTO: Radu Cugut. Radu has led the award-winning technology team that developed the Watchdog Report and services. He, his wife and son split their time between his home in Ave Maria, FL and his home in Timisoara, Romania where he oversees ve talented development professionals. Radu has a bachelors in Computer Science and a masters in Banking and Financial Information Systems, both from the West University of Timisoara. Chief Content Ocer: Joseph Burke, Ph.D. is responsible for the content development, analysis, and quality control for the Watchdog Report.
Recommended publications
  • Prostate Cancer in Focus

    Prostate Cancer in Focus

    PROSTATE CANCER IN FOCUS Current Developments in the Management of Prostate Cancer Section Editor: Andrew J. Armstrong, MD Prostate Cancer Prostate PSMA-Targeted Therapy in Prostate Cancer Scott T. Tagawa, MD, MS Professor of Medicine and Urology Weill Cornell Medicine New York, New York H&O What is prostate-specific membrane agent such as a monoclonal antibody might be able to antigen (PSMA), and what makes it a good target target a tumor without binding to other PSMA-positive for the treatment of prostate cancer? sites owing to its large size and physical inability to reach luminal sites of expression that are separated from the ST PSMA is a cell surface antigen that is expressed to vasculature by tight junctions. a limited degree on certain normal cells in the body but generally is highly overexpressed in the setting of prostate H&O How is PSMA positivity established? cancer. Normal cells that express PSMA are located in the prostate, salivary, and lacrimal glands; the proximal part ST Imaging and biopsy are the main ways to establish of the small intestine; the proximal renal tubules; and PSMA positivity. Multiple imaging modalities are avail- some ganglia. In the setting of prostate cancer, PSMA able worldwide. The agent indium In 111 capromab expression generally increases along with the cancer grade, pendetide (ProstaScint) has been approved for years in and it also increases following hormonal therapy. In addi- the United States, and the US Food and Drug Adminis- tion, PSMA expression tends to be higher in metastatic tration (FDA) approved the use of gallium Ga 68 PSMA- sites than in primary tumors.
  • Telaprevir (Incivek)

    Telaprevir (Incivek)

    © Hepatitis C Online PDF created September 25, 2021, 4:19 pm Telaprevir (Incivek) Discontinued. This treatment has been discontinued. Table of Contents Telaprevir Incivek Summary Drug Summary Adverse Effects Class and Mechanism Manufacturer for United States FDA Status Indications Dosing Clinical Use Cost and Medication Access Resistance Key Drug Interactions Full Prescribing Information Figures Drug Summary Although telaprevir was a promising direct-acting antiviral agent that had impact in the hepatitis C treatment field during 2011 to 2013, it was subsequently replaced by newer direct-acting antiviral agents that were more effective, better tolerated, and more convenient. Based on the dwindling role of telaprevir after newer direct-acting antiviral agents were approved, Vertex pharmaceuticals discontinued the sales and distribution of telaprevir in the United States in October 2014. Telaprevir does have some current importance since persons who previously failed a telaprevir-based regimen may have developed resistant associated variants, which could potentially impact subsequent therapy. Adverse Effects The most significant adverse effects reported in the main registration trials and in post-marketing experience were rash, anorectal complaints, and anemia. When comparing triple therapy of telaprevir, peginterferon, and ribavirin with dual therapy of peginterferon and ribavirin alone significant differences were noted with rash (56% versus 34%), anemia (36% versus 17%), and anorectal complaints that include anorectal discomfort, anal pruritus, and hemorrhoids (29% versus 7%). In most cases, the rash that develops is eczematous or maculopapular in character and mild to moderate in severity; the rash is typically manageable with good skin care and topical emollients or corticosteroids. In some instances, however, telaprevir has caused serious skin Page 1/5 rashes, including Steven's Johnson Syndrome (SJS), Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), and Toxic Epidermal Necrolysis (TEN).
  • AMGEN INC. V. SANOFI

    AMGEN INC. V. SANOFI

    Case: 20-1074 Document: 159 Page: 1 Filed: 06/21/2021 NOTE: This order is nonprecedential. United States Court of Appeals for the Federal Circuit ______________________ AMGEN INC., AMGEN MANUFACTURING, LIMITED, AMGEN USA, INC., Plaintiffs-Appellants v. SANOFI, AVENTISUB LLC, FKA AVENTIS PHARMACEUTICALS INC., REGENERON PHARMACEUTICALS INC., SANOFI-AVENTIS U.S. LLC, Defendants-Appellees ______________________ 2020-1074 ______________________ Appeal from the United States District Court for the District of Delaware in Nos. 1:14-cv-01317-RGA, 1:14-cv- 01349-RGA, 1:14-cv-01393-RGA, 1:14-cv-01414-RGA, Judge Richard G. Andrews. ______________________ JEFFREY A. LAMKEN, MoloLamken LLP, Washington, DC, filed a petition for rehearing en banc for plaintiffs-ap- pellants. Also represented by SARAH JUSTINE NEWMAN, MICHAEL GREGORY PATTILLO, JR.; SARA MARGOLIS, New York, NY; EMILY JOHNSON, ERICA S. OLSON, STEVEN TANG, STUART WATT, WENDY A. WHITEFORD, Amgen Inc., Thou- sand Oaks, CA; KEITH HUMMEL, Cravath Swaine & Moore LLP, New York, NY; WILLIAM G. GAEDE, III, McDermott Case: 20-1074 Document: 159 Page: 2 Filed: 06/21/2021 2 AMGEN INC. v. SANOFI Will & Emery LLP, Menlo Park, CA; CHRISTOPHER B. MEAD, Schertler Onorato Mead & Sears LLP, Washington, DC; JAMES L. HIGGINS, MELANIE K. SHARP, Young, Cona- way, Stargatt & Taylor, LLP, Wilmington, DE. Plaintiff- appellant Amgen Inc. also represented by SARAH CHAPIN COLUMBIA, McDermott, Will & Emery LLP, Boston, MA; LAUREN MARTIN, Quinn Emanuel Urquhart & Sullivan LLP, Boston, MA. MATTHEW WOLF, Arnold & Porter Kaye Scholer LLP, Washington, DC, filed a response for defendants-appellees. Also represented by VICTORIA REINES; DAVID K. BARR, DANIEL REISNER, New York, NY; DEBORAH E.
  • Refreshing the Biologic Pipeline 2020

    Refreshing the Biologic Pipeline 2020

    news feature Credit: Science Lab / Alamy Stock Photo Refreshing the biologic pipeline 2020 In the absence of face-to-face meetings, FDA and industry implemented regulatory workarounds to maintain drug and biologics approvals. These could be here to stay. John Hodgson OVID-19 might have been expected since 1996) — a small miracle in itself “COVID-19 confronted us with the need to severely impair drug approvals (Fig. 1 and Table 1). to better triage sponsors’ questions,” says Cin 2020. In the event, however, To the usual crop of rare disease and Peter Marks, the director of the Center for industry and regulators delivered a small genetic-niche cancer treatments, 2020 Biologics Evaluation and Research (CBER) miracle. They found workarounds and also added a chimeric antigen receptor at the FDA. “That was perhaps the single surrogate methods of engagement. Starting (CAR)-T cell therapy with a cleaner biggest takeaway from the pandemic related in January 2020, when the outbreak veered manufacturing process and the first to product applications.” Marks says that it westward, the number of face-to face approved blockbuster indication for a became very apparent with some COVID- meetings declined rapidly; by March, small-interfering RNA (siRNA) — the 19-related files that resolving a single they were replaced by Webex and Teams. European Medicines Agency’s (EMA) issue can help a sponsor enormously and (Secure Zoom meeting are to be added registration of the RNA interference accelerate the development cycle. Before this year.) And remarkably, by 31 December, (RNAi) therapy Leqvio (inclisiran) for COVID-19, it was conceivable that a small the US Food and Drug Administration cardiovascular disease.
  • ARK GENOMIC REVOLUTION MULTI SECTOR ETF (ARKG) HOLDINGS As of 09/27/2021

    ARK GENOMIC REVOLUTION MULTI SECTOR ETF (ARKG) HOLDINGS As of 09/27/2021

    ARK GENOMIC REVOLUTION MULTI SECTOR ETF (ARKG) HOLDINGS As of 09/27/2021 Company Ticker CUSIP Shares Market Value($) Weight(%) 1 TELADOC HEALTH INC TDOC 87918A105 3,937,797 531,208,815.30 6.99 2 EXACT SCIENCES CORP EXAS 30063P105 3,971,013 381,296,668.26 5.01 3 PACIFIC BIOSCIENCES OF CALIF PACB 69404D108 13,696,148 350,347,465.84 4.61 4 VERTEX PHARMACEUTICALS INC VRTX 92532F100 1,722,281 316,228,014.41 4.16 5 FATE THERAPEUTICS INC FATE 31189P102 4,825,395 312,926,865.75 4.12 6 IONIS PHARMACEUTICALS INC IONS 462222100 8,572,965 310,341,333.00 4.08 7 REGENERON PHARMACEUTICALS REGN 75886F107 430,742 275,201,063.80 3.62 8 TWIST BIOSCIENCE CORP TWST 90184D100 2,237,350 250,829,308.50 3.30 9 TAKEDA PHARMACEUTIC-SP ADR TAK UN 874060205 13,592,076 229,570,163.64 3.02 10 ACCOLADE INC ACCD 00437E102 5,268,242 226,850,500.52 2.98 11 INTELLIA THERAPEUTICS INC NTLA 45826J105 1,508,421 224,965,907.94 2.96 12 VEEVA SYSTEMS INC-CLASS A VEEV 922475108 741,198 222,307,516.14 2.92 13 CAREDX INC CDNA 14167L103 3,433,475 220,978,451.00 2.91 14 CRISPR THERAPEUTICS AG CRSP H17182108 1,804,041 210,044,493.63 2.76 15 INCYTE CORP INCY 45337C102 2,893,385 199,643,565.00 2.63 16 INVITAE CORP NVTA 46185L103 6,059,066 182,135,523.96 2.40 17 ADAPTIVE BIOTECHNOLOGIES ADPT 00650F109 4,888,391 178,377,387.59 2.35 18 BEAM THERAPEUTICS INC BEAM 07373V105 1,849,698 175,110,909.66 2.30 19 SIGNIFY HEALTH INC -CLASS A SGFY 82671G100 8,107,683 160,937,507.55 2.12 20 UIPATH INC - CLASS A PATH 90364P105 2,955,628 155,761,595.60 2.05 21 CASTLE BIOSCIENCES INC CSTL 14843C105 2,130,211
  • Vertex Pharmaceuticals Global Medical Affairs Pharmd Fellowship Program 2020 Message from Global Medical Affairs Leadership

    Vertex Pharmaceuticals Global Medical Affairs Pharmd Fellowship Program 2020 Message from Global Medical Affairs Leadership

    Vertex Pharmaceuticals Global Medical Affairs PharmD Fellowship Program 2020 Message from Global Medical Affairs Leadership Dear Candidates, Vertex Pharmaceuticals in collaboration with Northeastern University is privileged to host and expand the PharmD Fellowship Program. We are excited to work with our fellows as integral members of our team and facilitate in-depth exposure to a range of functional areas, offering them the critical opportunity to gain extensive experience in the biopharmaceutical industry. In addition to fostering each individual’s personal and professional growth, the program’s primary goal is to extend the visibility of valuable contributions that a Doctor of Pharmacy can bring to the pharmaceutical industry. At Vertex, our Global Medical Affairs fellows are highly encouraged to take on immersive projects, allowing them to work across departments with leaders in the industry. We advocate for them to partake in truly unique, impactful work that develops their skills, sparks curiosity, and drives the science. Vertex’s open and innovative culture allows the fellows to ask questions, challenge the status quo, and explore their interests across multiple expertise areas. As a pharmacist, I am extremely proud of the establishment of the Vertex PharmD Fellowship program in Global Medical Affairs and excited to welcome our future fellows. Vertex is an ideal place for fellows to start their professional career, and we are dedicated to the development of the next generation of pharmacist leaders in the biopharmaceutical industry. As Vertex continues to grow and evolve into a company in multiple disease areas, I am confident that our fellows will be an essential part of moving the needle to deliver on our commitment to patients.
  • VIRTUS ZEVENBERGEN INNOVATIVE GROWTH STOCK FUND SCHEDULE of INVESTMENTS (Unaudited) MARCH 31, 2021

    VIRTUS ZEVENBERGEN INNOVATIVE GROWTH STOCK FUND SCHEDULE of INVESTMENTS (Unaudited) MARCH 31, 2021

    VIRTUS ZEVENBERGEN INNOVATIVE GROWTH STOCK FUND SCHEDULE OF INVESTMENTS (Unaudited) MARCH 31, 2021 ($ reported in thousands) Shares Value Shares Value Footnote Legend: (1) Non-income producing. COMMON STOCKS—99.0% Industrials—3.9% Communication Services—9.3% Desktop Metal, Inc. (1) Country Weightings† Coursera, Inc.(1) 7,100 $ 320 Class A 359,800 $ 5,361 (1) Uber Technologies, United States 87% Netflix, Inc. 84,500 44,080 (1) Snap, Inc. Class A(1) 586,650 30,676 Inc. 897,900 48,944 Canada 7 Zillow Group, Inc. 54,305 Brazil 5 Class C(1) 434,335 56,307 Israel 1 Information Technology—43.9% Total 100% 131,383 (1) Coupa Software, Inc. 78,450 19,964 † (1) % of total investments as of March 31, 2021. Consumer Discretionary—25.3% fuboTV, Inc. 315,350 6,976 (1) NVIDIA Corp. 107,000 57,131 Airbnb, Inc. Class A 91,100 17,121 (1) Amazon.com, Inc.(1) 15,200 47,030 Okta, Inc. 235,575 51,928 (1) Paylocity Holding Chegg, Inc. 322,325 27,610 (1) (1) Corp. 110,750 19,916 Chewy, Inc. Class A 340,400 28,835 (1) Fiverr International PayPal Holdings, Inc. 198,850 48,289 Ltd.(1) 27,650 6,005 QUALCOMM, Inc. 204,050 27,055 RingCentral, Inc. Lululemon Athletica, (1) (1) Class A 129,800 38,665 Inc. 41,690 12,787 (1) (1) ServiceNow, Inc. 78,325 39,171 MercadoLibre, Inc. 48,225 70,994 (1) Peloton Interactive, Inc. Shopify, Inc. Class A 78,200 86,528 (1) Snowflake, Inc. Class A 336,850 37,876 (1) Tesla, Inc.(1) 162,740 108,699 Class A 110,700 25,381 Sprout Social, Inc.
  • Doctor of Pharmacy Fellowship Program

    Doctor of Pharmacy Fellowship Program

    2021-2022 Doctor of Pharmacy Fellowship Program Accelerate your career with one of our 1-year fellowship programs Transformative Therapies Targeting Cancer Seagen Inc. is a global biotechnology company dedicated to discovering, developing, and commercializing transformative YEARS: In oncology for 23+ years cancer medicines to make a meaningful difference in people’s lives. SIZE: Largest biotechnology company ADCETRIS® (brentuximab vedotin) and PADCEV® (enfortumab vedotin-ejfv) use based in the Pacific Northwest the company’s industry-leading antibody-drug conjugate (ADC) technology. ADCETRIS is approved in certain CD30-expressing lymphomas, and PADCEV is EMPLOYEES: 2,200+ employees approved in certain metastatic urothelial cancers. TUKYSA® (tucatinib), a small mole- worldwide cule tyrosine kinase inhibitor, is approved in certain HER2-positive metastatic breast cancers. The company is headquartered in Seattle, Washington area, with loca- PASSION: Helping people with cancer tions in California, Switzerland and the European Union. Beyond our approved prod- ucts, the company has established a pipeline of novel targeted therapies at various stages of clinical testing. OUR MISSION OUR VALUES To discover, develop, and Passion for helping patients commercialize transformative cancer Revolutionizing therapies for people medicines to make a meaningful living with cancer difference in people’s lives. Integrity Honesty, respect and trust guide us Scientific excellence Premier science empowers our passion We have built a strong Diversity, teamwork, and corporate culture around our mutual respect mission and values. Seagen Shared dedication and diverse embodies an entrepreneurial perspectives drive successful spirit that advances collaborations breakthrough therapies, Innovation which is why we are the Entrepreneurial spirit advances leader in antibody-drug breakthrough therapies conjugate technology.
  • BIOGEN INTERNATIONAL GMBH, Plaintiff-Appellant

    BIOGEN INTERNATIONAL GMBH, Plaintiff-Appellant

    Case: 20-1373 Document: 41 Page: 1 Filed: 04/21/2020 United States Court of Appeals for the Federal Circuit ______________________ BIOGEN INTERNATIONAL GMBH, Plaintiff-Appellant v. BANNER LIFE SCIENCES LLC, Defendant-Appellee ______________________ 2020-1373 ______________________ Appeal from the United States District Court for the District of Delaware in No. 1:18-cv-02054-LPS, Chief Judge Leonard P. Stark. ______________________ Decided: April 21, 2020 ______________________ JAMES B. MONROE, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, Washington, DC, for plaintiff-ap- pellant. Also represented by PAUL WILLIAM BROWNING, J. MICHAEL JAKES, LAURA POLLARD MASUROVSKY, JASON LEE ROMRELL. KYLE MUSGROVE, Parker Poe Adams & Bernstein LLP, Charlotte, NC, for defendant-appellee. Also represented by JOHN WORTHINGTON BATEMAN, ELIZABETH CROMPTON, SCOTT A. CUNNING, II, Washington, DC. ______________________ Case: 20-1373 Document: 41 Page: 2 Filed: 04/21/2020 2 BIOGEN INTERNATIONAL GMBH v. BANNER LIFE SCIENCES LLC Before LOURIE, MOORE, and CHEN, Circuit Judges. LOURIE, Circuit Judge. Biogen International GmbH (“Biogen”) appeals from a judgment of the United States District Court for the Dis- trict of Delaware that Banner Life Sciences LLC (“Banner”) does not infringe the extended portion of U.S. Patent 7,619,001 (the “’001 patent”), extended under the patent term restoration provisions of the Hatch-Waxman Act, Pub. L. No. 98-417, § 201, 98 Stat. 1585, 1598 (as codified at 35 U.S.C. § 156 (2018)). Biogen Int’l GmbH v. Banner Life Scis. LLC, No. 18-2054-LPS, 2020 WL 109499 (D. Del. Jan. 7, 2020) (“Decision”). Because the scope of a patent term extension under 35 U.S.C.
  • FTIF - Franklin Global Growth Fund August 31, 2021

    FTIF - Franklin Global Growth Fund August 31, 2021

    FTIF - Franklin Global Growth Fund August 31, 2021 FTIF - Franklin Global Growth August 31, 2021 Fund Portfolio Holdings The following portfolio data for the Franklin Templeton funds is made available to the public under our Portfolio Holdings Release Policy and is "as of" the date indicated. This portfolio data should not be relied upon as a complete listing of a fund's holdings (or of a fund's top holdings) as information on particular holdings may be withheld if it is in the fund's interest to do so. Additionally, foreign currency forwards are not included in the portfolio data. Instead, the net market value of all currency forward contracts is included in cash and other net assets of the fund. Further, portfolio holdings data of over-the-counter derivative investments such as Credit Default Swaps, Interest Rate Swaps or other Swap contracts list only the name of counterparty to the derivative contract, not the details of the derivative. Complete portfolio data can be found in the semi- and annual financial statements of the fund. Security Security Shares/ Market % of Coupon Maturity Identifier Name Positions Held Value TNA Rate Date G6095L109 APTIV PLC 70,000 $10,653,300 3.09% N/A N/A 045327103 ASPEN TECHNOLOGY INC 58,000 $7,511,000 2.18% N/A N/A BRIGHT HORIZONS FAMILY SOLUTIONS 109194100 49,000 $7,142,240 2.07% N/A N/A INC BROADRIDGE FINANCIAL SOLUTIONS 11133T103 46,000 $7,922,120 2.30% N/A N/A INC 124765108 CAE INC 360,000 $10,394,547 3.01% N/A N/A CHARLES RIVER LABORATORIES 159864107 27,000 $11,984,220 3.47% N/A N/A INTERNATIONAL
  • United States Securities and Exchange Commission Form

    United States Securities and Exchange Commission Form

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2005 VERTEX PHARMACEUTICALS INCORPORATED (Exact name of registrant as specified in its charter) MASSACHUSETTS 000-19319 04-3039129 (State or other jurisdiction of (Commission File Number) (IRS Employer Identification incorporation) No.) 130 Waverly Street Cambridge, Massachusetts 02139 (Address of principal executive offices) (Zip Code) (617) 444-6100 Registrant’s telephone number, including area code: Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Item 8.01. Other Events. On June 17, 2005, Vertex Pharmaceuticals Incorporated and Merck & Co., Inc. issued a joint press release that announced the initiation of an additional Phase I study with VX-680, a small molecule inhibitor of Aurora kinases. A copy of that press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Item 9.01.
  • Human Sequencing Resource with UK Biobank

    Human Sequencing Resource with UK Biobank

    January 8, 2018 Regeneron Forms Consortium of Leading Life Sciences Companies to Accelerate Largest Widely-Available 'Big Data' Human Sequencing Resource with UK Biobank By end of 2019, Regeneron plans to sequence the exomes of all 500,000 people within the UK Biobank resource, all with associated health records, creating an unprecedented resource linking human genetic variations to human biology and disease AbbVie, Alnylam Pharmaceuticals, AstraZeneca, Biogen and Pfizer will join Regeneron to co-fund one of the industry's most ambitious 'pre-competitive' research efforts Exome sequencing data and findings will be openly available to other researchers TARRYTOWN, N.Y., Jan. 8, 2018 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), along with new collaborators AbbVie, Alnylam Pharmaceuticals, AstraZeneca, Biogen and Pfizer Inc., today announced the formation of a major 'pre-competitive' consortium to fund the generation of genetic exome sequence data from the 500,000 volunteer participants who make up the UK Biobank health resource. The newly announced collaborators will each commit $10 million to enable a dramatic acceleration of sequencing timelines, and additional companies are considering joining the consortium. Regeneron will conduct the sequencing effort. The sequencing data will be paired with detailed, de-identified medical and health records within the UK Biobank resource, including enhanced measures such as brain, heart and body imaging, to create an unparalleled resource for linking human genetic variations to human biology and disease. It was originally planned that sequencing of all 500,000 samples in the UK Biobank would be completed by 2022, with the first 50,000 people sequenced during 2017 with funding from Regeneron and GlaxoSmithKline.